Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Single-Arm, Open-Label Study to Assess the Safety and Efficacy of Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia - The CORAL Study

NCT05209308 is registered in ClinicalTrials.gov with MEI Pharma, Inc. as lead sponsor.

NCT NCT05209308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05209308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Single-Arm, Open-Label Study to Assess the Safety and Efficacy of Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia - The CORAL Study
Lead sponsor
MEI Pharma, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
November 22, 2022
Completion date
March 15, 2023
Enrollment
0 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cll